Stem cell sourcing plays a crucial role in unleashing the full potential of therapeutic exosomes. It must meet the dual requirements of potency, inherited from stem cells, and availability, achieved through high-yield production capacities in a cost-effective manner. 

Our approach to availability centers around plasmid-based hTert immortalization, providing our cell line with an impressive 100-fold increase in doubling population capacity. This ensures stable and continuous production, ideal for large-scale exosome manufacturing. With cloning capacities enabling the creation of multiple Master Cell Banks, each capable of producing billions of doses of EVs, we ensure ample supply for therapeutic treatments. 

Beneath the surface lies the remarkable potency of our EVs, evidenced by their anti-inflammatory and regenerative effects in pre-clinical studies. Derived exclusively from umbilical cord-derived Wharton’s jelly through a single sourcing (cloning) approach, our cell line offers a consistent and reliable platform for optimizing both quality and yield through priming and induction techniques. 

Unlock the therapeutic potential of exosomes with our exclusive immortalized cell line, poised to revolutionize regenerative medicine and advance patient care.